We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) ended the recent trading session at $10.60, demonstrating a -2.75% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.57%, while the tech-heavy Nasdaq added 0.04%.
Prior to today's trading, shares of the infectious disease drug developer had gained 20.98% outpaced the Medical sector's loss of 0.72% and the S&P 500's gain of 12.24%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
For the full year, the Zacks Consensus Estimates project earnings of $0.93 per share and a revenue of $611.67 million, demonstrating changes of +55% and +19.89%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.14% lower within the past month. Adma Biologics is currently a Zacks Rank #3 (Hold).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 11.78. This denotes a discount relative to the industry average Forward P/E of 21.51.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 147, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Adma Biologics (ADMA - Free Report) ended the recent trading session at $10.60, demonstrating a -2.75% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.57%, while the tech-heavy Nasdaq added 0.04%.
Prior to today's trading, shares of the infectious disease drug developer had gained 20.98% outpaced the Medical sector's loss of 0.72% and the S&P 500's gain of 12.24%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
For the full year, the Zacks Consensus Estimates project earnings of $0.93 per share and a revenue of $611.67 million, demonstrating changes of +55% and +19.89%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.14% lower within the past month. Adma Biologics is currently a Zacks Rank #3 (Hold).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 11.78. This denotes a discount relative to the industry average Forward P/E of 21.51.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 147, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.